The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1296
Dutasteride (Avodart) with Tamsulosin (Flomax) for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Revised 7/27/11: Since this article was published, the FDA has approved a fixed-dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (Jalyn) for once-daily treatment of benign prostatic hyperplasia (BPH).

The FDA has approved the use of the 5α-reductase inhibitor dutasteride (Avodart – GlaxoSmithKline) together with the alpha1-blocker tamsulosin (Flomax – Boehringer Ingelheim) for treatment of benign prostatic hyperplasia (BPH). Use of an alpha1-blocker with a 5α-reductase inhibitor has been a common practice for years, but FDA approval of a particular combination permits the manufacturers to add an indication for it in both package inserts, recommend dosage for combination use, and advertise the benefits of using the 2 drugs together.

MECHANISM OF ACTION — Alpha1-blockers ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dutasteride (Avodart) with Tamsulosin (Flomax) for Benign Prostatic Hyperplasia
Article code: 1296b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian